Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting

Bibliography

• Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006;102:1884-98
   PubMed Web of Science ®Google Scholar
• Gan TJ. Postoperative nausea and vomiting: can it be eliminated? JAMA 2002;287:1233-6
   PubMed Web of Science ®Google Scholar
• Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment and prevention. Anesthesiology 1992;77:162-84
   PubMed Web of Science ®Google Scholar
• Apfel CC, Krake P, Eberhart LHJ, et al. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002;88:234-40
   PubMed Web of Science ®Google Scholar
• Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007;105:1615-28
   PubMed Web of Science ®Google Scholar
• Grelot L, Miller AD. Vomiting: its ins and outs. News Physiol Sci 1994;9:142-6
   Google Scholar
• Fukuda H, Koga T. The Bötzinger complex as the pattern generator for retching and vomiting in the dog. Neurosci Res 1991;12:471-85
   PubMed Web of Science ®Google Scholar
• Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111:106S-12S
   PubMed Web of Science ®Google Scholar
• Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neurosci Res 1992;14:166-79
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Joshi GP, Brichant JF. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth 2009;103:7-13
   PubMed Web of Science ®Google Scholar
• Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006;19:606-11
   PubMed Web of Science ®Google Scholar
• http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/95/FileName/B04E66A7A692B605D0A8196CBC881255/PI_Zofran.pdf
   Google Scholar
• Tzvetkov MV, Saadatmand AR, Bokelmann K, et al. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron. Pharmacogenomics J 2012;12:22-9
   PubMed Web of Science ®Google Scholar
• Mackinnon JWM, Collin DT. The chemistry of ondansetron. Eur J Cancer Clin Oncol 1989;25(Suppl 1):S61
   PubMedGoogle Scholar
• Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95-109
   PubMed Web of Science ®Google Scholar
• Aapro M. 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005;69:97-109
   PubMed Web of Science ®Google Scholar
• Butler A, Hill JM, Ireland SJ, et al. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988;94:397-412
   PubMed Web of Science ®Google Scholar
• Bodhankar SL, Thakurdesai PA, Maurya OP. Effects of (RS)-Ondansetron and its enantiomers on QTc interval in Rats. Pharmacologyonline 2006;3:153-8
   Google Scholar
• Shinde J, Mandora VP, Joshi PK, Erram SS. Efficacy and safety of R-Ondansetron 4 mg versus racemic Ondansetron 8 mg: results of a randomized, double blind, multicentric clinical trial. Indian Med Gazette 2005;139:444-7
   Google Scholar
• Garud KL, Godbole S, Mankar S, Pathak S. Efficacy and safety of R(+) Ondansetron solution in the treatment of nausea and vomiting in children: results of an open-label, non-comparative, prospective clinical study. Indian Med Gazette 2006;140:112-14
   Google Scholar
• Boeijinga PH, Galvan M, Baron BM, et al. Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992;219:9-13
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugiura M, Higo K, et al. Receptor occupancy theory-based analysis of antiemetic effectsand standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol 2004;54:185-90
   PubMed Web of Science ®Google Scholar
• Ayuhara Y, Takayanagi R, Okuyama K. Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5- HT3 receptor antagonists. Int J Clin Oncol 2009;14:518-24
   PubMed Web of Science ®Google Scholar
• Van Den Berg CM, Kazmil Y, Stewart J, et al. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository and i.v. infusion. Am J Health Syst Pharm 2000;57:1046-50
   PubMed Web of Science ®Google Scholar
• Pritchard JF. Ondansetron metabolism and pharmacokinetics. Semin Oncol 1992;19(Suppl 10):95-155
   Google Scholar
• Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs 2005;19:225-38
   PubMed Web of Science ®Google Scholar
• Sphar-Schopfer IA, Lerman J, Sikich N, et al. Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose and throat surgery. Clin Pharmacol Ther 1995;58:361-21
   Google Scholar
• Mondick JT, Johnson BM, Haberer LJ, et al. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months. Eur J Clin Pharmacol 2010;66:77-86
   PubMed Web of Science ®Google Scholar
• Figg WD, Dukes GE, Pritchard F, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996;36:206-25
   PubMed Web of Science ®Google Scholar
• Amantea MA, Yarboro C, Forrest A, et al. Population pharmacokinetics of intravenous and oral ondansetron in patients with systemic lupus erythematosus (SLE). J Clin Pharmacol 1993;33:1004
   Google Scholar
• Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting. Do CYP2D6 alleles copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005;102:543-9
   PubMed Web of Science ®Google Scholar
• Keiser R, Sezer O, Papies A, et al. Patient–tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-11
   PubMed Web of Science ®Google Scholar
• Janicki PK. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit 2005;11. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2:171-82
   PubMed Web of Science ®Google Scholar
• Stamer UM, Lee EH, Rauers NI, et al. CYP2D6- and CYP3A- dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg 2011;113:48-54
   PubMed Web of Science ®Google Scholar
• Gwak HS, Oh IS, Chun IK. Transdermal delivery of ondansetron hydrochloride: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm 2004;30:187-94
   PubMed Web of Science ®Google Scholar
• Obataa Y, Ashitakaa Y, Kikuchia S, et al. A statistical approach to the development of a transdermal delivery system for ondansetron. Int J Pharm 2010;399:87-93
   PubMedGoogle Scholar
• Can AS, Erdal M, Güngör S, Özsoy Y. Optimization and characterization of chitosan films for transdermal delivery of ondansetron. Molecules 2013;18:5455-71
   PubMed Web of Science ®Google Scholar
• Dharani S, Shayeda Formulation and in in vitro evaluation of mucoadhesive buccal patches of ondansetron hydrochloride. Int J Pharm Sci Nanotechnol 2010;3:860-6
   Google Scholar
• Park DM, Song YK, Jee JP, et al. Development of chitosan-based ondansetron buccal delivery system for the treatment of emesis. Drug Dev Ind Pharm 2012;38:1077-8
   PubMed Web of Science ®Google Scholar
• Koland M, Charyulu RN, Vijayanarayana K, Prabhu P. In vitro and in vivo evaluation of chitosan buccal films of ondansetron hydrochloride. Int J Pharm Investig 2011;1:164-71
   Google Scholar
• Prasanna RI, Anitha P, Chetty CM. Formulation and evaluation of bucco-adhesive tablets of sumatriptan succinate. Int J Pharm Investig 2011;1:182-91
   PubMedGoogle Scholar
• Cho E, Gwak H, Chun I. Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm 2008;349:101-7
   PubMed Web of Science ®Google Scholar
• Gungor S, Okyar A, Erturk-Toker S, et al. Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes. Drug Dev Ind Pharm 2010;36:806-13
   PubMed Web of Science ®Google Scholar
• Kovac A, McKenzie R, O'Connor T, et al. Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. Eur J Anaesthesiol Suppl 1992;9:37-47
   Google Scholar
• Du Pen S, Scuderi P, Wetchler B, et al. Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. Eur J Anaesthesiol Suppl 1992;9:55-62
   Google Scholar
• Larijani GE, Gratz I, Afshar M, Minassian S. Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. Anesth Analg 1991;73:246-9
   PubMed Web of Science ®Google Scholar
• Tramèr MR, Reynolds DJM, Moore RA, et al. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a qualitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997;87:1277-89
   PubMed Web of Science ®Google Scholar
• Sun R, Klein KW, White PF. The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. Anesth Analg 1997;84:331-6
   PubMed Web of Science ®Google Scholar
• Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998;86:274-82
   PubMed Web of Science ®Google Scholar
• Cruz NI, Portila P, Vela RE. Timing of ondansetron administration to prevent postoperative nausea and vomiting PRHSJ. 2008;27:43-7
   Google Scholar
• Kovac AL, O'Connor TA, Pearman MH, et al. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo- controlled multicenter trial. J Clin Anesth 1999;11:453-9
   PubMed Web of Science ®Google Scholar
• Naguib M, El Bakry AK, Khoshim MHB, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized double- blind comparison with placebo. Can J Anaesth 1996;43:226-31
   PubMed Web of Science ®Google Scholar
• Jokela J, Koivuranta M, Kangas–Saarela T, et al. Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery. Acta Anaesthesiol Scand 2002;46:519-24
   PubMed Web of Science ®Google Scholar
• Metaxari M, Papaioannou A, Petrou A, et al. Antiemetic prophylaxis in thyroid surgery: a randomized, double-blind comparison of three 5-HT3 agents. J Anesth 2011;25:356-62
   PubMed Web of Science ®Google Scholar
• Korttila K, Clergue F, Leeser J, et al. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. Acta Anaesthesiol Scand 1997;41:914-22
   PubMed Web of Science ®Google Scholar
• Zarate E, Watcha MF, White PF, et al. Comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg 2000;90:1352-8
   PubMed Web of Science ®Google Scholar
• Meyer TA, Roberson CR, Rajab MH, et al. Dolasetron versus ondansetron for the treatment of postoperative nausea and vomiting. Anesth Analg 2005;100:373-7
   PubMed Web of Science ®Google Scholar
• Moon YE. JooJ, Kim J E, Lee Y. Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study. Br J Anaesth 2012;108:417-22
   PubMed Web of Science ®Google Scholar
• Kim YY, Moon SY, Song DU, et al. Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery. Korean J Anesthesiol 2013;64:122-6
   PubMedGoogle Scholar
• Cholwill JM, Wright W, Hobbs GJ, et al. Comparison of ondansetron and cyclizine for prevention of nausea and vomiting after day- case gynaecological laparoscopy. Br J Anaesth 1999;83:611-14
   PubMed Web of Science ®Google Scholar
• Grimsehl K, Whiteside JB, Mackenzie N. Comparison of cyclizine and ondansetron for the prevention of PONV in laparoscopic day –case gynaecological surgery. Anaesthesia 2002;57:61-5
   PubMed Web of Science ®Google Scholar
• Kothari SN, Boyd WC, Bottcher ML, et al. Antiemetic efficacy of prophylactic dimenhydrinate (Dramamine) vs ondansetron (Zofran): a randomized, prospective trial in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2000;14:926-9
   PubMed Web of Science ®Google Scholar
• Ahmed AB, Hobbs GJ, Curran JP. Randomized, placebo-controlled trial of combination antiemetic prophylaxis for day-case gynaecological laparoscopic surgery. Br J Anaesth 2000;85:678-82
   PubMed Web of Science ®Google Scholar
• Sniadach SM, Alberts MS. A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy. Anesth Analg 1997;85:797-800
   PubMed Web of Science ®Google Scholar
• Singla NK, Singla SK, Chung F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and post discharge nausea and vomiting in high-risk patients. Anesthesiology 2010;113:74-82
   PubMed Web of Science ®Google Scholar
• Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441-51
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007;99:202-11
   PubMed Web of Science ®Google Scholar
• McQueen KD, Milton JD. Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients. Ann Pharmacother 1994;28:85-92
   PubMed Web of Science ®Google Scholar
• Finn AL. Toxicity and side effects of ondansetron. Semin Oncol 1992;19:53-60
   PubMed Web of Science ®Google Scholar
• Lee CY, Ratnapalan S, Thompson M, et al. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma. Can J Clin Pharmacol 2010;17:1-4
   Google Scholar
• ZOFRAN® (ondansetron hydrochloride) injection; ZOFRAN®(ondansetron hydrochloride) injection premixed [package insert]. GlaxoSmithKline; Research Triangle Park (NC): 2001
   Google Scholar
• Kuryshev Y, Brown AM, Wang L, et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000;295:614-20
   PubMed Web of Science ®Google Scholar
• Charbit B, Alvarez JC, Dasque E, et al. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology 2008;109:206-12
   PubMed Web of Science ®Google Scholar
• McKechnie K, Froese A. Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome. Can J Anaesth 2010;57:453-7
   PubMed Web of Science ®Google Scholar
• Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100
   PubMed Web of Science ®Google Scholar
• Chan MT, Choi KC, Gin T, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006;103:1155-62
   PubMed Web of Science ®Google Scholar
• Siu SSN, Chan MTV, Lau TK. Placental transfer of ondansetron during early human pregnancy. Clin Pharmacokinet 2006;45:419-23
   PubMed Web of Science ®Google Scholar
• Pasternak B, Svanström H. HviidA. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013;368:814-23
   PubMed Web of Science ®Google Scholar
• Einarson A, Maltepe C, Navioz Y, et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-3
   PubMed Web of Science ®Google Scholar
• Anderka M, Mitchell AA, Louik C, et al. National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012;94:22-30
   PubMed Web of Science ®Google Scholar
• Villikka K, Kivistö KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999;65:377-81
   PubMed Web of Science ®Google Scholar
• Johnson B, Adams L, Lu E, et al. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 2009;17:1177-85
   PubMed Web of Science ®Google Scholar
• Rauers NI, Stüber F, Lee EH, et al. Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study. J Pain 2010;11:1274-8
   PubMed Web of Science ®Google Scholar
• Vale C, Oliveira F, Assunção J, et al. Co-administration of ondansetron decreases the analgesic efficacy of tramadol in humans. Pharmacology 2011;88:182-7
   PubMed Web of Science ®Google Scholar
• Arcioni R, dellaRocca M, Romanò S, et al. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002;94:1553-7
   PubMed Web of Science ®Google Scholar
• Broome IJ, Robb HM, Raj N, et al. The use of tramadol following day-case oral surgery. Anaesthesia 1999;54:289-92
   PubMed Web of Science ®Google Scholar